Skip to content

DCN for ECD Livers

Safe Transplantation of Extended Criteria Donor Livers: Two-center Experience With Resuscitation and Viability Assessment of 206 Livers Using Sequential Hypo- and Normothermic Machine Perfusion

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06804746
Enrollment
143
Registered
2025-02-03
Start date
2019-03-01
Completion date
2025-10-31
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Keywords

Liver Transplantation, Machine Perfusion, Extended Criteria Donors

Brief summary

The goal of this observational study is to learn whether extended criteria donor livers can be safely transplanted after sequential hypo- and normothermic machine perfusion in recipients requiring a liver transplant for end-stage liver disease, including a long-term follow-up. The main questions it aims to answer are: * Death censored graft-survival * Overall patient survival * Frequency of frequent post-transplant complications (e.g. non-anastomotic biliary strictures)

Detailed description

With the increasing shortage of suitable donor livers for transplantation, extended criteria donor (ECD) livers may bridge the gap between available donor organs and donor livers needed. However, these ECD livers are associated with a higher risk of posttransplant complications. With the development of machine perfusion (MP) strategies over the recent years, (dual) hypothermic oxygenated perfusion ((D)HOPE) is established as a safe and effective way to reduce ischemia reperfusion injury. This leads to a decrease in early allograft dysfunction and non-anastomotic biliary strictures (NAS). On the other hand, normothermic machine perfusion (NMP) is mainly used for hepatobiliary functional assessment of liver grafts prior to transplantation. Combining both perfusion techniques through 1 hour of controlled oxygenated rewarming (COR), enables safe selection and transplantation of ECD livers after DHOPE-COR-NMP. Long-term outcomes are now available from two centers.

Interventions

PROCEDUREDHOPE-COR-NMP

Resuscitation and viability assessment through the previously published protocol of sequential hypo- and normothermic liver machine perfusion with controlled oxygenated rewarming (DHOPE-COR-NMP) based on a blood-based perfusate.

Sponsors

Erasmus Medical Center
Lead SponsorOTHER
University Medical Center Groningen
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (\>18 years old) * Donor livers that required resuscitation and viability assessment through the previously published sequential hypo- and normothermic liver machine perfusion (DHOPE-COR-NMP) protocol based on a blood-based perfusate.

Exclusion criteria

* Multiorgan transplantation * Split liver transplant * Living donor liver transplantation * Previous donor organ perfusion (e.g. Normothermic Regional Perfusion)

Design outcomes

Primary

MeasureTime frameDescription
Death-censored graft survival1 year post-transplantTime from liver transplantation until re-transplantation or death due to graft dysfunction, with censoring of subjects who died with a functioning graft.

Secondary

MeasureTime frameDescription
Overall patient survival1 year post-transplantTime from liver transplantation until all-cause death
• Overall graft survival1 year post-transplantTime from liver transplantation until re-transplantation or all-cause death.
Number of participants with primary non functionFrom transplantation until 7 days post-transplantLivers failing to sustain their primary function, leading to death or re-transplantation within 7 days of the primary procedure, in the presence of patent blood supply and outflow (8).
Occurrence of hepatic arterial thrombosis1 year post-transplantRadiologically or surgically proven thrombosis of the hepatic artery.
Occurrence of portal vein thrombosis1 year post-transplantRadiologically or surgically proven thrombosis of the portal vein.
Occurrence of venous outflow tract obstruction1 year post-transplantRadiologically or surgically proven thrombosis of the main hepatic veins or the inferior vena cava.
Occurrence of non-anastomotic biliary strictures1 year post-transplantAny irregularity or narrowing of the lumen of the intrahepatic or extrahepatic donor bile ducts, excluding the biliary anastomosis, diagnosed with the use of cholangiography in combination with clinical symptoms (e.g., jaundice or cholangitis) or an elevation of cholestatic laboratory variables, in the presence of a patent hepatic artery (5).
Occurrence of anastomotic biliary strictures1 year post-transplantStrictures occurring at the anastomosis of donor choledochal duct and recipient choledochal duct or jejunal Roux-limb.
Occurrence of biliary leakageFrom 3 days after transplantation until the the first year post-transplantFluid with an elevated (\>3x serum) bilirubin level in the abdominal drain or intra-abdominal fluid on or after post-operative day 3 or the need for radiological intervention (i.e. interventional drainage) owing to biliary collections or re-laparotomy due to biliary peritonitis (9).
Biliary complications: as a composite1 year post-transplantA composite of individually studied outcome measures (reported as one single outcome measure), composed of: non-anastomotic biliary strictures, anastomotic biliary strictures and biliary leakage.
Intensive care stayFrom transplantation until discharge from the Intensive care unit to the ward after transplantation or date of death from any cause during initial admission, whichever came first, assessed up to 6 monthsIntensive care stay post-transplantation
Total hospital stayFrom transplantation until discharge after transplantation, or date of death from any cause during initial admission, whichever came first, assessed up to 6 monthsDefined as total hospital stay from transplantation until discharge, including intensive care unit stay

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026